# Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

> **NCT03344640** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 96 (actual)

## Conditions studied

- Tendinopathy

## Interventions

- **DRUG:** secukinumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03344640
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2019-08-02
- **Final completion:** 2019-10-17
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344640, "Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03344640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*